Literature DB >> 26105946

Random urine albumin:creatinine ratio in high-risk pregnancy - Is it clinically useful?

Dane A De Silva1, Anne C Halstead2, Anne-Marie Côté3, Yasser Sabr4, Peter von Dadelszen5, Laura A Magee6.   

Abstract

We evaluated the frequency of measurable albuminuria (⩾6.00mg/L) for albumin:creatinine ratios (ACr) among 160 consecutive women attending high-risk clinics. Of last urine samples before delivery, 76 had measurable albuminuria and 41/76 (53.9%) had ACr ⩾2mg/mmol of which 7.3% had normal pregnancy outcome. 84 samples had albuminuria <6.00mg/L and 43/84 (51.2%) had ACr ⩾2mg/mmol of which 25.6% had normal pregnancy outcome (p=0.025). Excluding 48/160 (30.0%) dilute samples (urinary creatinine <3mM), no samples with unmeasurable albuminuria had ACr ⩾2mg/mmol. In pregnancy, urine is often dilute and without measurable albuminuria, leading to a clinically relevant proportion of false positive results by ACr.
Copyright © 2013 International Society for the Study of Hypertension in Pregnancy. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Albumin:creatinine ratio; Hypertension; Microalbuminuria; Pre-eclampsia; Pregnancy; Proteinuria

Year:  2013        PMID: 26105946     DOI: 10.1016/j.preghy.2013.02.001

Source DB:  PubMed          Journal:  Pregnancy Hypertens        ISSN: 2210-7789            Impact factor:   2.899


  3 in total

Review 1.  Pre-eclampsia: an update.

Authors:  Peter von Dadelszen; Laura A Magee
Journal:  Curr Hypertens Rep       Date:  2014-08       Impact factor: 5.369

Review 2.  Preventing deaths due to the hypertensive disorders of pregnancy.

Authors:  Peter von Dadelszen; Laura A Magee
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2016-06-28       Impact factor: 5.237

3.  Unexpected random urinary protein:creatinine ratio results-limitations of the pyrocatechol violet-dye method.

Authors:  Dane A De Silva; Anne C Halstead; Anne-Marie Côté; Yasser Sabr; Peter von Dadelszen; Laura A Magee
Journal:  BMC Pregnancy Childbirth       Date:  2013-07-17       Impact factor: 3.007

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.